Occult primary

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 9, Issue 12, 2011, Pages 1358-1395

  Ettinger, David S ^a   Agulnik, Mark ^a   Cates, Justin M M ^a   Cristea, Mihaela ^a   Denlinger, Crystal S ^a   Eaton, Keith D ^a   Fidias, Panagiotis M ^a   Gierada, David ^a   Gockerman, Jon P ^a   Handorf, Charles R ^a   Iyer, Renuka ^a   Lenzi, Renato ^a   Phay, John ^a   Rashid, Asif ^a   Saltz, Leonard ^a   Shulman, Lawrence N ^a   Smerage, Jeffrey B ^a   Varadhachary, Gauri R ^a   Zager, Jonathan S ^a   Zhen, Weining ^a  

^a NONE

Author keywords

Carcinoma of unknown primary; Chemotherapy; Metastatic; NCCN clinical practice guidelines; NCCN guidelines; Occult primary

Indexed keywords

ANTINEOPLASTIC AGENT; CALRETININ; CARBOPLATIN; CD45 ANTIGEN; CISPLATIN; DOCETAXEL; EPITHELIAL MEMBRANE ANTIGEN; ESTROGEN RECEPTOR; ETOPOSIDE; FLUOROURACIL; GEMCITABINE; MAMMAGLOBIN; MELAN A; MESOTHELIN; MONOCLONAL ANTIBODY D2-40; PACLITAXEL; PLACENTA LIKE ALKALINE PHOSPHATASE; PROGESTERONE RECEPTOR; PROSTATE SPECIFIC ANTIGEN; PROTEIN; PROTEIN S 100; THYROGLOBULIN; THYROID TRANSCRIPTION FACTOR 1; TRANSCRIPTION FACTOR CDX2; UNCLASSIFIED DRUG; UROPLAKIN; VILLIN; WT1 PROTEIN; ANTIBODY;

ADENOCARCINOMA; BILE DUCT CARCINOMA; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER OF UNKNOWN PRIMARY SITE; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; COLORECTAL CANCER; CONTINUOUS INFUSION; ENDOMETRIOID CARCINOMA; HUMAN; LEUKEMIA; LIFE EXPECTANCY; LUNG ADENOCARCINOMA; LUNG SMALL CELL CANCER; LYMPH NODE DISSECTION; LYMPHOMA; MELANOMA; MESOTHELIOMA; METASTASIS; MULTIPLE CYCLE TREATMENT; NON SEMINOMATOUS GERMINOMA; OVARY CANCER; PANCREAS ADENOCARCINOMA; PRACTICE GUIDELINE; PROGNOSIS; PROSTATE ADENOCARCINOMA; REVIEW; SQUAMOUS CELL CARCINOMA; STOMACH ADENOCARCINOMA; THYROID CANCER; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA; ALGORITHM; ARTICLE; CARCINOMA; FEMALE; LEGAL ASPECT; LYMPH NODE METASTASIS; MALE; MEDICAL SOCIETY; METHODOLOGY; MOLECULAR DIAGNOSIS; ONCOLOGY; ORGANIZATION AND MANAGEMENT; PATHOLOGY; UNITED STATES;

ADENOCARCINOMA; ALGORITHMS; ANTIBODIES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA; FEMALE; HUMANS; LYMPHATIC METASTASIS; MALE; MEDICAL ONCOLOGY; MOLECULAR DIAGNOSTIC TECHNIQUES; NEOPLASMS, UNKNOWN PRIMARY; PRACTICE GUIDELINES AS TOPIC; SOCIETIES, MEDICAL; UNITED STATES;

EID: 83755178047     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2011.0117     Document Type: Review

References (107)

1. Greco FA, Hainsworth JD. Cancer of unknown primary site. In: DeVita VT, Lawrence TS, Rosenburg SA, eds. DeVita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. Vol. 2. 8th ed. Philadelphia: Lippincott Williams N& Wilkins; 2008:2363-2387.
2. Greco FA, Hainsworth JD. Tumors of unknown origin. CA Cancer J Clin 1992;42:96-115.
3. Pavlidis N. Cancer of unknown primary: biological and clinical characteristics. Ann Oncol 2003;14(Suppl 3):iii11-18. (Pubitemid 36874143)
4. Pavlidis N, Briasoulis E, Hainsworth J, Greco FA. Diagnostic and therapeutic management of cancer of an unknown primary. Eur J Cancer 2003;39:1990-2005. (Pubitemid 37297755)
5. Hainsworth JD, Lawrence M, Weiss LM. Carcinoma of an unknown primary site. In: Pazdur R, Wagman LD, Camphausen C, Hoskins WJ, eds. Cancer Management: A Multidisciplinary Approach, 12th ed. Norwalk (CT): CMPMedica LLC; 2009.
6. Bugat R, Bataillard A, Lesimple T, et al. Summary of the standards, options and recommendations for the management of patients with carcinoma of unknown primary site (2002). Br J Cancer 2003;89(Suppl 1):S59-66. (Pubitemid 37076150)
7. Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011;61:212-236.
8. Hemminki K, Ji J, Sundquist J, Shu X. Familial risks in cancer of unknown primary: tracking the primary sites. J Clin Oncol 2011;29:435-440.
9. Blaszyk H, Hartmann A, Bjornsson J. Cancer of unknown primary: clinicopathologic correlations. APMIS 2003;111:1089-1094. (Pubitemid 38091247)
10. Hillen HF. Unknown primary tumours. Postgrad Med J 2000;76:690-693.
11. van de Wouw AJ, Jansen RL, Speel EJ, Hillen HF. The unknown biology of the unknown primary tumour: a literature review. Ann Oncol 2003;14:191-196. (Pubitemid 36305428)
12. Pavlidis N, Fizazi K. Cancer of unknown primary (CUP). Crit Rev Oncol Hematol 2005;54:243-250. (Pubitemid 40693686)
13. Briasoulis E, Tsokos M, Fountzilas G, et al. Bcl2 and p53 protein expression in metastatic carcinoma of unknown primary origin: biological and clinical implications. A Hellenic Co-operative Oncology Group study. Anticancer Res 1998;18:1907-1914. (Pubitemid 28344848)
14. Stelow EB, French CA. Carcinomas of the upper aerodigestive tract with rearrangement of the nuclear protein of the testis (NUT) gene (NUT midline carcinomas). Adv Anat Pathol 2009;16:92-96.
15. French CA, Kutok JL, Faquin WC, et al. Midline carcinoma of children and young adults with NUT rearrangement. J Clin Oncol 2004;22:4135-4139. (Pubitemid 41185183)
16. Hainsworth JD, Greco FA. Treatment of patients with cancer of an unknown primary site. N Engl J Med 1993;329:257-263. (Pubitemid 23203818)
17. Hainsworth JD, Johnson DH, Greco FA. Poorly differentiated neuroendocrine carcinoma of unknown primary site. A newly recognized clinicopathologic entity. Ann Intern Med 1988;109:364-371.
18. Moertel CG, Kvols LK, O'Connell MJ, Rubin J. Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms. Cancer 1991;68:227-232.
19. Hess KR, Abbruzzese MC, Lenzi R, et al. Classification and regression tree analysis of 1000 consecutive patients with unknown primary carcinoma. Clin Cancer Res 1999;5:3403-3410.
20. Chorost MI, Lee MC, Yeoh CB, et al. Unknown primary. J Surg Oncol 2004;87:191-203. (Pubitemid 39167387)
21. Abbruzzese JL, Abbruzzese MC, Hess KR, et al. Unknown primary carcinoma: natural history and prognostic factors in 657 consecutive patients. J Clin Oncol 1994;12:1272-1280. (Pubitemid 24173944)
22. Culine S. Prognostic factors in unknown primary cancer. Semin Oncol 2009;36:60-64.
23. van de Wouw AJ, Jansen RL, Griffioen AW, Hillen HF. Clinical and immunohistochemical analysis of patients with unknown primary tumour. A search for prognostic factors in UPT. Anticancer Res 2004;24:297-301. (Pubitemid 38279722)
24. Hainsworth JD, Fizazi K. Treatment for patients with unknown primary cancer and favorable prognostic factors. Semin Oncol 2009;36:44-51.
25. Lenzi R, Hess KR, Abbruzzese MC, et al. Poorly differentiated carcinoma and poorly differentiated adenocarcinoma of unknown origin: favorable subsets of patients with unknown-primary carcinoma? J Clin Oncol 1997;15:2056-2066. (Pubitemid 27209537)
26. Jereczek-Fossa BA, Jassem J, Orecchia R. Cervical lymph node metastases of squamous cell carcinoma from an unknown primary. Cancer Treat Rev 2004;30:153-164. (Pubitemid 38418053)
27. Dabbs DJ. Diagnostic Immunohistochemistry, 1st ed. Philadelphia: Churchill Livingstone; 2002.
28. Wick MR. Immunohistochemical approaches to the diagnosis of undifferentiated malignant tumors. Ann Diagn Pathol 2008;12:72-84. (Pubitemid 350299213)
29. Oien KA. Pathologic evaluation of unknown primary cancer. Semin Oncol 2009;36:8-37.
30. Varadhachary GR, Greco FA. Overview of patient management and future directions in unknown primary carcinoma. Semin Oncol 2009;36:75-80.
31. Bahrami A, Truong LD, Ro JY. Undifferentiated tumor: true identity by immunohistochemistry. Arch Pathol Lab Med 2008;132:326-348. (Pubitemid 351328809)
32. Chu PG, Weiss LM. Keratin expression in human tissues and neoplasms. Histopathology 2002;40:403-439. (Pubitemid 34535443)
33. Chu P, Wu E, Weiss LM. Cytokeratin 7 and cytokeratin 20 expression in epithelial neoplasms: a survey of 435 cases. Mod Pathol 2000;13:962-972.
34. Varadhachary GR, Abbruzzese JL, Lenzi R. Diagnostic strategies for unknown primary cancer. Cancer 2004;100:1776-1785. (Pubitemid 38529553)
35. Kaufmann O, Fietze E, Mengs J, Dietel M. Value of p63 and cytokeratin 5/6 as immunohistochemical markers for the differential diagnosis of poorly differentiated and undifferentiated carcinomas. Am J Clin Pathol 2001;116:823-830. (Pubitemid 33108152)
36. Wick MR, Lillemoe TJ, Copland GT, et al. Gross cystic disease fluid protein-15 as a marker for breast cancer: immunohistochemical analysis of 690 human neoplasms and comparison with alpha-lactalbumin. Hum Pathol 1989;20:281-287. (Pubitemid 19081966)
37. Bender RA, Erlander MG. Molecular classification of unknown primary cancer. Semin Oncol 2009;36:38-43.
38. Monzon FA, Koen TJ. Diagnosis of metastatic neoplasms: molecular approaches for identification of tissue of origin. Arch Pathol Lab Med 2010;134:216-224.
39. Talantov D, Baden J, Jatkoe T, et al. A quantitative reverse transcriptase-polymerase chain reaction assay to identify metastatic carcinoma tissue of origin. J Mol Diagn 2006;8:320-329. (Pubitemid 44063808)
40. Varadhachary GR, Talantov D, Raber MN, et al. Molecular profiling of carcinoma of unknown primary and correlation with clinical evaluation. J Clin Oncol 2008;26:4442-4448.
41. Ma XJ, Patel R, Wang X, et al. Molecular classification of human cancers using a 92-gene real-time quantitative polymerase chain reaction assay. Arch Pathol Lab Med 2006;130:465-473.
42. Greco FA, Spigel DR, Yardley DA, et al. Molecular profiling in unknown primary cancer: accuracy of tissue of origin prediction. Oncologist 2010;15:500-506.
43. Hainsworth JD, Spigel DR, Rubin MS, et al. Treatment of carcinoma of unknown primary site (CUP) directed by molecular profiling diagnosis: a prospective, phase II trial [abstract]. J Clin Oncol 2010;28(Suppl 1):Abstract 10540.
44. Greco FA, Lennington WJ, Spigel DR, et al. Carcinoma of unknown primary site (CUP): outcomes in patients with a colorectal molecular profile treated with site-specific chemotherapy [abstract]. J Clin Oncol 2011;29(Suppl 1):Abstract 3563.
45. Dumur CI, Lyons-Weiler M, Sciulli C, et al. Interlaboratory performance of a microarray-based gene expression test to determine tissue of origin in poorly differentiated and undifferentiated cancers. J Mol Diagn 2008;10:67-77. (Pubitemid 351184837)
46. Monzon FA, Lyons-Weiler M, Buturovic LJ, et al. Multicenter validation of a 1,550-gene expression profile for identification of tumor tissue of origin. J Clin Oncol 2009;27:2503-2508.
47. Monzon FA, Dumur CI. Diagnosis of uncertain primary tumors with the Pathwork tissue-of-origin test. Expert Rev Mol Diagn 2010;10:17-25.
48. Rosenfeld N, Aharonov R, Meiri E, et al. MicroRNAs accurately identify cancer tissue origin. Nat Biotechnol 2008;26:462-469. (Pubitemid 351501813)
49. Rosenwald S, Gilad S, Benjamin S, et al. Validation of a microRNA-based qRT-PCR test for accurate identification of tumor tissue origin. Mod Pathol 2010;23:814-823.
50. Varadhachary GR, Spector Y, Abbruzzese JL, et al. Prospective gene signature study using microRNA to identify the tissue of origin in patients with carcinoma of unknown primary (CUP). Clin Cancer Res 2011;17:4063-4070.
51. Woods RL, Fox RM, Tattersall MH, et al. Metastatic adenocarcinomas of unknown primary site: a randomized study of two combination-chemotherapy regimens. N Engl J Med 1980;303:87-89. (Pubitemid 10073317)
52. Goldberg RM, Smith FP, Ueno W, et al. 5-fluorouracil, adriamycin, and mitomycin in the treatment of adenocarcinoma of unknown primary. J Clin Oncol 1986;4:395-399. (Pubitemid 16133093)
53. Pasterz R, Savaraj N, Burgess M. Prognostic factors in metastatic carcinoma of unknown primary. J Clin Oncol 1986;4:1652-1657. (Pubitemid 17188933)
54. Eagan RT, Therneau TM, Rubin J, et al. Lack of value for cisplatin added to mitomycin-doxorubicin combination chemotherapy for carcinoma of unknown primary site. A randomized trial. Am J Clin Oncol 1987;10:82-85. (Pubitemid 17007913)
55. Milliken ST, Tattersall MH, Woods RL, et al. Metastatic adenocarcinoma of unknown primary site. A randomized study of two combination chemotherapy regimens. Eur J Cancer Clin Oncol 1987;23:1645-1648. (Pubitemid 18044641)
56. Alberts AS, Falkson G, Falkson HC, van der Merwe MP. Treatment and prognosis of metastatic carcinoma of unknown primary: analysis of 100 patients. Med Pediatr Oncol 1989;17:188-192. (Pubitemid 19187085)
57. Becouarn Y, Brunet R, Barbe-Gaston C. Fluorouracil, doxorubicin, cisplatin and altretamine in the treatment of metastatic carcinoma of unknown primary. Eur J Cancer Clin Oncol 1989;25:861-865. (Pubitemid 19164331)
58. Schneider BJ, El-Rayes B, Muler JH, et al. Phase II trial of carboplatin, gemcitabine, and capecitabine in patients with carcinoma of unknown primary site. Cancer 2007;110:770-775. (Pubitemid 47257653)
59. Greco FA, Burris HA III, Litchy S, et al. Gemcitabine, carboplatin, and paclitaxel for patients with carcinoma of unknown primary site: a Minnie Pearl Cancer Research Network study. J Clin Oncol 2002;20:1651-1656. (Pubitemid 34260547)
60. Moller AKH, Pedersen KD, Gothelf A, Daugaard G. Paclitaxel, cisplatin and gemcitabine in treatment of carcinomas of unknown primary site, a phase II study. Acta Oncol 2010;49:423-430.
61. Hainsworth JD, Erland JB, Kalman LA, et al. Carcinoma of unknown primary site: treatment with 1-hour paclitaxel, carboplatin, and extended-schedule etoposide. J Clin Oncol 1997;15:2385-2393. (Pubitemid 27251142)
62. Greco FA, Gray J, Burris HA, et al. Taxane-based chemotherapy for patients with carcinoma of unknown primary site. Cancer J 2001;7:203-212.
63. Hainsworth JD, Spigel DR, Farley C, et al. Phase II trial of bevacizumab and erlotinib in carcinomas of unknown primary site: the Minnie Pearl Cancer Research Network. J Clin Oncol 2007;25:1747-1752. (Pubitemid 46797956)
64. Hainsworth JD, Spigel DR, Thompson DS, et al. Paclitaxel/carboplatin plus bevacizumab/erlotinib in the first-line treatment of patients with carcinoma of unknown primary site. Oncologist 2009;14:1189-1197.
65. van der Gaast A, Verweij J, Henzen-Logmans SC, et al. Carcinoma of unknown primary: identification of a treatable subset? Ann Oncol 1990;1:119-122. (Pubitemid 20215452)
66. Hainsworth JD, Johnson DH, Greco FA. Cisplatin-based combination chemotherapy in the treatment of poorly differentiated carcinoma and poorly differentiated adenocarcinoma of unknown primary site: results of a 12-year experience. J Clin Oncol 1992;10:912-922.
67. Briasoulis E, Kalofonos H, Bafaloukos D, et al. Carboplatin plus paclitaxel in unknown primary carcinoma: a phase II Hellenic Cooperative Oncology Group Study. J Clin Oncol 2000;18:3101-3107.
68. Greco FA, Burris HA, Erland JB, et al. Carcinoma of unknown primary site. Cancer 2000;89:2655-2660.
69. Hainsworth JD, Spigel DR, Clark BL, et al. Paclitaxel/carboplatin/ etoposide versus gemcitabine/irinotecan in the first-line treatment of patients with carcinoma of unknown primary site: a randomized, phase III Sarah Cannon Oncology Research Consortium Trial. Cancer J 2010;16:70-75.
70. Huebner G, Link H, Kohne CH, et al. Paclitaxel and carboplatin vs gemcitabine and vinorelbine in patients with adeno- or undifferentiated carcinoma of unknown primary: a randomised prospective phase II trial. Br J Cancer 2009;100:44-49.
71. Greco FA, Rodriguez GI, Shaffer DW, et al. Carcinoma of unknown primary site: sequential treatment with paclitaxel/carboplatin/etoposide and gemcitabine/irinotecan: a Minnie Pearl Cancer Research Network phase II trial. Oncologist 2004;9:644-652. (Pubitemid 39546405)
72. Greco FA, Erland JB, Morrissey LH, et al. Carcinoma of unknown primary site: phase II trials with docetaxel plus cisplatin or carboplatin. Ann Oncol 2000;11:211-215. (Pubitemid 30148737)
73. Pentheroudakis G, Briasoulis E, Kalofonos HP, et al. Docetaxel and carboplatin combination chemotherapy as outpatient palliative therapy in carcinoma of unknown primary: a multicentre Hellenic Cooperative Oncology Group phase II study. Acta Oncol 2008;47:1148-1155.
74. Culine S, Lortholary A, Voigt JJ, et al. Cisplatin in combination with either gemcitabine or irinotecan in carcinomas of unknown primary site: results of a randomized phase II study-trial for the French Study Group on Carcinomas of Unknown Primary (GEFCAPI 01). J Clin Oncol 2003;21:3479-3482. (Pubitemid 46594080)
75. Pouessel D, Culine S, Becht C, et al. Gemcitabine and docetaxel as front-line chemotherapy in patients with carcinoma of an unknown primary site. Cancer 2004;100:1257-1261. (Pubitemid 38325954)
76. Jeremic B, Zivic DJ, Matovic M, Marinkovic J. Cisplatin and 5-fluorouracil as induction chemotherapy followed by radiation therapy in metastatic squamous cell carcinoma of an unknown primary tumor localized to the neck. A phase II study. J Chemother 1993;5:262-265. (Pubitemid 23309985)
77. Khansur T, Allred C, Little D, Anand V. Cisplatin and 5-fluorouracil for metastatic squamous cell carcinoma from unknown primary. Cancer Invest 1995;13:263-266.
78. Hitt R, Lopez-Pousa A, Martinez-Trufero J, et al. Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer. J Clin Oncol 2005;23:8636-8645. (Pubitemid 46211506)
79. Pointreau Y, Garaud P, Chapet S, et al. Randomized trial of induction chemotherapy with cisplatin and 5-fluorouracil with or without docetaxel for larynx preservation. J Natl Cancer Inst 2009;101:498-506.
80. Spigel DR, Hainsworth JD, Greco FA. Neuroendocrine carcinoma of unknown primary site. Semin Oncol 2009;36:52-59.
81. Hainsworth JD, Spigel DR, Litchy S, Greco FA. Phase II trial of paclitaxel, carboplatin, and etoposide in advanced poorly differentiated neuroendocrine carcinoma: a Minnie Pearl Cancer Research Network Study. J Clin Oncol 2006;24:3548-3554. (Pubitemid 46630525)
82. Ekeblad S, Sundin A, Janson ET, et al. Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors. Clin Cancer Res 2007;13:2986-2991. (Pubitemid 46849574)
83. Kulke MH, Stuart K, Enzinger PC, et al. Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. J Clin Oncol 2006;24:401-406. (Pubitemid 46630459)
84. Okamoto H, Watanabe K, Kunikane H, et al. Randomised phase III trial of carboplatin plus etoposide vs split doses of cisplatin plus etoposide in elderly or poor-risk patients with extensive disease small-cell lung cancer: JCOG 9702. Br J Cancer 2007;97:162-169. (Pubitemid 47057464)
85. Fjällskog ML, Granberg DP, Welin SL, et al. Treatment with cisplatin and etoposide in patients with neuroendocrine tumors. Cancer 2001;92:1101-1107. (Pubitemid 32861657)
86. Bucci MK, Bevan A, Roach M. Advances in radiation therapy: conventional to 3D, to IMRT, to 4D, and beyond. CA Cancer J Clin 2005;55:117-134. (Pubitemid 40372906)
87. Chen K, Chen X. Positron emission tomography imaging of cancer biology: current status and future prospects. Semin Oncol 2011;38:70-86.
88. Demir H, Berk F, Raderer M, et al. The role of nuclear medicine in the diagnosis of cancer of unknown origin. Q J Nucl Med Mol Imaging 2004;48:164-173. (Pubitemid 39248303)
89. Delgado-Bolton RC, Fernandez-Perez C, Gonzalez-Mate A, Carreras JL. Meta-analysis of the performance of 18F-FDG PET in primary tumor detection in unknown primary tumors. J Nucl Med 2003;44:1301-1314. (Pubitemid 39655191)
90. Kole AC, Nieweg OE, Pruim J, et al. Detection of unknown occult primary tumors using positron emission tomography. Cancer 1998;82:1160-1166. (Pubitemid 28136532)
91. Seve P, Billotey C, Broussolle C, et al. The role of 2-deoxy-2-[F-18] fluoro-D-glucose positron emission tomography in disseminated carcinoma of unknown primary site. Cancer 2007;109:292-299. (Pubitemid 46116455)
92. Podoloff DA, Ball DW, Ben-Josef E, et al. NCCN Task Force: clinical utility of PET in a variety of tumor types. J Natl Compr Canc Netw 2009;7(Suppl 2):1-26.
93. Townsend DW, Carney JPJ, Yap JT, Hall NC. PET/CT today and tomorrow. J Nucl Med 2004;45(Suppl 1):14.
94. Gutzeit A, Antoch G, Kuhl H, et al. Unknown primary tumors: detection with dual-modality PET/CT-initial experience. Radiology 2005;234:227-234. (Pubitemid 39662772)
95. Hu M, Zhao W, Zhang PL, et al. Clinical applications of 18F-fluorodeoxyglucose positron emission tomography/computed tomography in carcinoma of unknown primary. Chin Med J (Engl) 2011;124:1010-1014.
96. Nanni C, Rubello D, Castellucci P, et al. Role of 18F-FDG PET-CT imaging for the detection of an unknown primary tumour: preliminary results in 21 patients. Eur J Nucl Med Mol Imaging 2005;32:589-592. (Pubitemid 41214202)
97. Pelosi E, Pennone M, Deandreis D, et al. Role of whole body positron emission tomography/computed tomography scan with 18F-fluorodeoxyglucose in patients with biopsy proven tumor metastases from unknown primary site. Q J Nucl Med Mol Imaging 2006;50:15-22.
98. Kwee TC, Kwee RM. Combined FDG-PET/CT for the detection of unknown primary tumors: systematic review and meta-analysis. Eur Radiol 2009;19:731-744.
99. Ambrosini V, Nanni C, Rubello D, et al. 18F-FDG PET/CT in the assessment of carcinoma of unknown primary origin. Radiol Med 2006;111:1146-1155. (Pubitemid 46024906)
100. Bhatia SK, Saclarides TJ, Witt TR, et al. Hormone receptor studies in axillary metastases from occult breast cancers. Cancer 1987;59:1170-1172. (Pubitemid 17040399)
101. Bleicher RJ, Morrow M. MRI and breast cancer: role in detection, diagnosis, and staging. Oncology (Williston Park) 2007;21:1521-1528.
102. Olson JA, Morris EA, Van Zee KJ, et al. Magnetic resonance imaging facilitates breast conservation for occult breast cancer. Ann Surg Oncol 2000;7:411-415. (Pubitemid 30439299)
103. Stomper PC, Waddell BE, Edge SB, Klippenstein DL. Breast MRI in the evaluation of patients with occult primary breast carcinoma. Breast J 1999;5:230-234. (Pubitemid 29365317)
104. Buchanan CL, Morris EA, Dorn PL, et al. Utility of breast magnetic resonance imaging in patients with occult primary breast cancer. Ann Surg Oncol 2005;12:1045-1053. (Pubitemid 41660680)
105. Muggia FM, Baranda J. Management of peritoneal carcinomatosis of unknown primary tumor site. Semin Oncol 1993;20:268-272. (Pubitemid 23171896)
106. Strnad CM, Grosh WW, Baxter J, et al. Peritoneal carcinomatosis of unknown primary site in women. A distinctive subset of adenocarcinoma. Ann Intern Med 1989;111:213-217. (Pubitemid 19190913)
107. Guarischi A, Keane TJ, Elhakim T. Metastatic inguinal nodes from an unknown primary neoplasm. A review of 56 cases. Cancer 1987;59:572-577. (Pubitemid 17002441)